TYGLAR
Dissolution or liquidationSummary
The KBO register records for TYGLAR the legal situation: dissolution or liquidation; this is today's state according to the register itself, which carries no start date. The 2025 annual accounts show equity of €39k and a net result of €5k.
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Filed after the deadline
The financial year that closed on 27-03-2025 was due by 27-10-2025 and was filed on 24-11-2025, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 7 filingsDeviation from the deadline
2025
28 d late
2024
3 d late
2023
31 d late
2022
16 d early
2021
4 d early
2020
8 d early
2019
29 d late
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 27-03-2026 and is due by 27-10-2026. Nothing is late today.
Companies Code · seven monthsPosition in the running window
27-03-2026 close25-09-2026 today27-10-2026 deadline
Financials · fiscal year 2025, micro schema
Equity
€39k▼ 61.7%
2024 · €103k
2019: €15k
2020: €12k▼ -21.2% vs 2019
2021: €-108k▼ -1020% vs 2020
2022: €-163k▼ -50.7% vs 2021lowest in 7 years
2023: €107k▲ +166% vs 2022highest in 7 years
2024: €103k▼ -3.6% vs 2023
2025: €39k▼ -61.7% vs 2024
2019 → 2025
Total assets
€41k▼ 61.9%
2024 · €107k
2019: €161k
2020: €385k▲ +139% vs 2019highest in 7 years
2021: €196k▼ -49.0% vs 2020
2022: €184k▼ -6.1% vs 2021
2023: €112k▼ -39.1% vs 2022
2024: €107k▼ -4.5% vs 2023
2025: €41k▼ -61.9% vs 2024lowest in 7 years
2019 → 2025
Net result
€5k
2024 · €-4k
2019: €-191k
2020: €-349k▼ -82.3% vs 2019lowest in 7 years
2021: €-120k▲ +65.7% vs 2020
2022: €-55k▲ +54.3% vs 2021
2023: €270k▲ +593% vs 2022highest in 7 years
2024: €-4k▼ -101% vs 2023
2025: €5k▲ +238% vs 2024
2019 → 2025
Working capital
€39k▼ 61.7%
2024 · €103k
2019: €13k
2020: €162k▲ +1177% vs 2019highest in 7 years
2021: €-3k▼ -102% vs 2020
2022: €-77k▼ -2683% vs 2021lowest in 7 years
2023: €107k▲ +239% vs 2022
2024: €103k▼ -3.6% vs 2023
2025: €39k▼ -61.7% vs 2024
2019 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-108k-€-163k▼ 50.7%€107k€103k▼ 3.6%€39k▼ 61.7%
2021: €-108k
2022: €-163k▼ -50.7% vs 2021lowest in 5 years
2023: €107k▲ +166% vs 2022highest in 5 years
2024: €103k▼ -3.6% vs 2023
2025: €39k▼ -61.7% vs 2024
Operating result€-117k-€-53k▲ 54.7%€271k€-4k€5k
2021: €-117klowest in 5 years
2022: €-53k▲ +54.7% vs 2021
2023: €271k▲ +609% vs 2022highest in 5 years
2024: €-4k▼ -101% vs 2023
2025: €5k▲ +217% vs 2024
Net result€-120k-€-55k▲ 54.3%€270k€-4k€5k
2021: €-120klowest in 5 years
2022: €-55k▲ +54.3% vs 2021
2023: €270k▲ +593% vs 2022highest in 5 years
2024: €-4k▼ -101% vs 2023
2025: €5k▲ +238% vs 2024
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2025: €5k after a loss of €4k in 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €41k
Equity
€39k ▼ 61.7%
Debt
€1k ▼ 66.9%
Debt's share of the balance-sheet total falls from 3.8% to 3.3%. Equity and debt are lower.
Key figures and ratios
Current ratio
30.12▲
2024 · 26.16
Debt to equity
0.03▼
2024 · 0.04
ROE
13.4%▲
2024 · -3.7%
ROA
13.0%▲
2024 · -3.6%
Debt ≤ 1 year
€1k▼
2024 · €4k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 27 lines
Balance sheet
Code20242025
Assets
Total assets20/58€107k€41k▼
Current assets29/58€107k€41k▼
Amounts receivable within one year40/41€961€1k▲
Trade receivables40€71€71=
Other amounts receivable41€890€1k▲
Cash at bank and in hand54/58€106k€39k▼
Equity and liabilities
Total equity and liabilities10/49€107k€41k▼
Equity10/15€103k€39k▼
Contributions10/11€552k€552k=
Profit (loss) carried forward14€-449k€-443k▲
Advance to shareholders on the distribution of net assets19-€69k
Amounts payable17/49€4k€1k▼
Amounts payable within one year42/48€4k€1k▼
Trade debts44€3k€96▼
Suppliers440/4€3k€96▼
Taxes, remuneration and social security45€1k€1k▼
Taxes450/3€1k€1k▼
Income statement
Code20242025
Other operating charges640/8-€353
Gross operating margin9900€-4k€5k▲
Operating profit (loss)9901€-4k€5k▲
Financial income75/76B-€801
Recurring financial income75-€801
Profit (loss) for the period before taxes9903€-4k€5k▲
Profit (loss) for the period9904€-4k€5k▲
Profit (loss) for the period to be appropriated9905€-4k€5k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-449k€-443k▲
Profit (loss) brought forward from the previous period14P€-445k€-449k▼
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | €45 | - | €369k | - | - | - |
| Remuneration, social security and pensions62 | €26k | - | - | - | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €29k | €29k | €31k | - | - | - |
| Other operating charges640/8 | €284 | €435 | €622 | - | €353 | - |
| Gross operating margin9900 | €-62k | €-24k | €302k | €-4k | €5k | ▲ 226% |
| Operating profit (loss)9901 | €-117k | €-53k | €271k | €-4k | €5k | ▲ 217% |
| Financial income75/76B | €21 | €0 | €948 | - | €801 | - |
| Recurring financial income75 | €21 | €0 | €948 | - | €801 | - |
| Financial charges65/66B | €2k | €1k | €3k | - | - | - |
| Recurring financial charges65 | €2k | €1k | €3k | - | - | - |
| Profit (loss) for the period before taxes9903 | €-120k | €-55k | €270k | €-4k | €5k | ▲ 238% |
| Income taxes67/77 | €25 | - | - | - | - | - |
| Profit (loss) for the period9904 | €-120k | €-55k | €270k | €-4k | €5k | ▲ 238% |
| Profit (loss) for the period to be appropriated9905 | €-120k | €-55k | €270k | €-4k | €5k | ▲ 238% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €196k | €184k | €112k | €107k | €41k | ▼ 61.9% |
| Fixed assets21/28 | €164k | €158k | - | - | - | - |
| Intangible fixed assets21 | €45k | €37k | - | - | - | - |
| Tangible fixed assets22/27 | €119k | €122k | - | - | - | - |
| Plant, machinery and equipment23 | €1k | €122k | - | - | - | - |
| Assets under construction and advance payments27 | €118k | - | - | - | - | - |
| Current assets29/58 | €32k | €26k | €112k | €107k | €41k | ▼ 61.9% |
| Stocks and contracts in progress3 | €13k | €25k | - | - | - | - |
| Stocks30/36 | €13k | €25k | - | - | - | - |
| Amounts receivable within one year40/41 | €2k | €1k | €2k | €961 | €1k | ▲ 48.6% |
| Trade receivables40 | - | - | €71 | €71 | €71 | = |
| Other amounts receivable41 | €2k | €1k | €2k | €890 | €1k | ▲ 52.5% |
| Cash at bank and in hand54/58 | €18k | €278 | €111k | €106k | €39k | ▼ 62.9% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €196k | €184k | €112k | €107k | €41k | ▼ 61.9% |
| Equity10/15 | €-108k | €-163k | €107k | €103k | €39k | ▼ 61.7% |
| Contributions10/11 | €552k | €552k | €552k | €552k | €552k | = |
| Profit (loss) carried forward14 | €-660k | €-714k | €-445k | €-449k | €-443k | ▲ 1.2% |
| Advance to shareholders on the distribution of net assets19 | - | - | - | - | €69k | - |
| Amounts payable17/49 | €304k | €347k | €5k | €4k | €1k | ▼ 66.9% |
| Amounts payable after more than one year17 | €269k | €244k | - | - | - | - |
| Financial debts170/4 | €59k | €34k | - | - | - | - |
| Other amounts payable178/9 | €210k | €210k | - | - | - | - |
| Amounts payable within one year42/48 | €35k | €103k | €5k | €4k | €1k | ▼ 66.9% |
| Current portion of amounts payable after more than one year42 | €25k | €25k | - | - | - | - |
| Financial debts43 | - | €13k | - | - | - | - |
| Credit institutions430/8 | - | €13k | - | - | - | - |
| Trade debts44 | €10k | €65k | €5k | €3k | €96 | ▼ 96.5% |
| Suppliers440/4 | €10k | €65k | €5k | €3k | €96 | ▼ 96.5% |
| Taxes, remuneration and social security45 | €384 | €115 | - | €1k | €1k | ▼ 8.3% |
| Taxes450/3 | €384 | €115 | - | €1k | €1k | ▼ 8.3% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €-120k | €-55k | €270k | €-4k | €5k | ▲ 238% |
| + Depreciation and write-downs630 | €29k | €29k | €31k | - | - | - |
| Operating cash flow (approximation) | €-90k | €-26k | €300k | €-4k | €5k | ▲ 238% |
| Investment in fixed assets (approximation) | - | €-23k | - | - | - | - |
| Change in cash | - | €-17k | €110k | €-4k | €-67k | ▼ 1,453% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2025
24-11
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 28 days late
27-03
Financial
Back to profitnet €5k
Net result €5k after one loss-making year.
2024
30-10
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 3 days late
31-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 31 days late
2023
31-12
Financial
Back to profitnet €270k
Net result €270k after 4 loss-making years.
31-12
Financial
Liquidity times 85current ratio 21.27
Current ratio from 0.25 to 21.27; short-term debt falls from €103k to €5k.
31-12
Financial
Equity above €100kEq €107k
Equity rises from €-163k to €107k.
15-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
27-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
23-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
31-12
Financial
Weakest financial yearnet €-349k
Net result drops to €-349k, the lowest in the series.
31-12
Financial
Liquidity doublescurrent ratio 3.16
Current ratio from 1.45 to 3.16.
29-08
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 4 acts read
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Mechelen · 2 establishment units since 2019
Ground area
3,857 m²
Building footprint
710 m²
Volume, LiDAR
8,622 m³
2 parcels, Flanders · tallest building 16.4 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
TYGLAR
since 20192.286.986.717
Juniorslaan(LST) 120, 2811 Mechelen
since 20192.294.465.120
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 12020A0645/00A000 | Flanders | 2,609 m² | 1 · 219 m² | 9.0 m · 2 fl. |
| 24062A1082/00T000 | Flanders | 1,248 m² | 1 · 491 m² | 16.4 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Mar Jaen
BE 0736.939.583
Antwerpen · Eq €39,867
Ergotrics
BE 0506.642.480
Turnhout · Eq €39,085
Docteur Stefan CONSTANTINESCU
BE 0546.822.454
Sint-Pieters-Woluwe · Eq €40,458
DEDAL
BE 1001.005.158
Elsene · Eq €38,533
EUROPHARMEDTECH
BE 0685.431.593
Ganshoren · Eq €41,127
Of 762 companies in sector 72101 we hold annual accounts for 481. 223 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded25-02-2019
Fiscal year end27-03
Activities, NACEBEL 2025
72101Research and development on biotechnology
46460Wholesale of pharmaceutical and medical goods
Scores and ratios are computed by Checked and are not a credit decision.